Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)

Catherine C Smith, MD, Kimberly Lin, BS, Elisabeth Lasater, PhD, Whitney Stewart, BS, Lauren E Damon, Andrew Kasarskis, PhD, Ali Bashir, PhD, Matthew Pendleton, Robert Sebra, Alexander E Perl, MD, Mai H Le, MD, Chao Zhang, PhD, Brian West, Ph.D., Neil P. Shah, MD, PhD

Blood (2013) 122 (21): 3938.

https://doi.org/10.1182/blood.V122.21.3938.3938

Published: 2013

Journal Articles

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Ravi Vij, MBBS, MD, Jonathan L. Kaufman, MD, Andrzej J Jakubowiak, MD, PhD, A. Keith Stewart, MBChB, Sundar Jagannath, MD, Vishal Kukreti, MD, FRCPC, Kevin T. McDonagh, MD, Melissa Alsina, MD, Nizar J Bahlis, MD, Andrew Belch, MD, Frederic J. Reu, MD, Nashat Y Gabrail, MD, Jeffrey Matous, MD, David H. Vesole, MD, PhD, Robert Z. Orlowski, MD, PhD, Mai H. Le, MD, Peter Lee, MD, PhD, Michael Wang, MD, The MMRC

Blood (2010) 116 (21): 1938.

https://doi.org/10.1182/blood.V116.21.1938.1938

Published: 2010

Journal Articles

Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Sundar Jagannath, MD, Ravi Vij, MBBS, MD, Jonathan L. Kaufman, MD, Thomas Martin, MD, Ruben Niesvizky, MD, Nashat Y Gabrail, MD, Melissa Alsina, MD, Alvin F. Wong, PharmD, Mai H. Le, MD, Leanne McCulloch, PharmD, Alison L. Hannah, MD, Michael Kauffman, MD, PhD, David Samuel diCapua Siegel, MD, PhD

Blood (2010) 116 (21): 1953.

https://doi.org/10.1182/blood.V116.21.1953.1953

Published: 2010

Journal Articles

Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.

Ravi Vij, MD, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., A. Keith Stewart, MD, Sundar Jagannath, MD, Sagar Lonial, MD, Suzanne Trudel, MD, Andrzej J Jakubowiak, MD, PhD, Andrew Belch, MD, Melissa Alsina, MD, Nizar J Bahlis, MD, Mai H. Le, MD, Scott Cruickshank, BA, MS, Mark K Bennett, PhD, Susan Molineaux, PhD, Michael Kauffman, MD, PhD, David Siegel, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 430.

https://doi.org/10.1182/blood.V114.22.430.430

Published: 2009

Journal Articles

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

Luhua Wang, MD, David Siegel, Jonathan L. Kaufman, MD, A. Keith Stewart, MD, Andrzej J Jakubowiak, MD, PhD, Melissa Alsina, MD, Vishal Kukreti, MD, FRCPC, Nizar J Bahlis, MD, Kevin T. McDonagh, MD, Andrew Belch, MD, Michael Sebag, MD, PhD, Nashat Gabrail, MD, Mai H. Le, MD, Mark K Bennett, PhD, Lori Kunkel, MD, Michael Kauffman, MD, PhD, Robert Z Orlowski, M.D., Ph.D., Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 302.

https://doi.org/10.1182/blood.V114.22.302.302

Published: 2009

Journal Articles

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

David Siegel, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., Jonathan L. Kaufman, MD, A. Keith Stewart, MD, Vishal Kukreti, MD, FRCPC, Melissa Alsina, MD, Andrzej J Jakubowiak, MD, PhD, Sundar Jagannath, MD, Kevin T. McDonagh, MD, Andrew Belch, MD, Nizar J Bahlis, MD, Chaim Shustik, MD, Mai H. Le, MD, Lori Kunkel, MD, Mark K Bennett, PhD, Michael Kauffman, MD, PhD, Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 303.

https://doi.org/10.1182/blood.V114.22.303.303

Published: 2009

NARROW

Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

Email alerts

ASH Publications

American Society of Hematology

Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only